Unknown document format

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

Dated July 12, 2006

PreMD Inc.

Commission File Number 1-31360

615-4211 Yonge Street Toronto, Ontario M2P 2A9 CANADA

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F ý Form 40-F "

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other

Commission filing on EDGAR.			
Indicate by check mark whether be furnishing the information to the C			
	Yes "	No ý	
If "Yes" is marked, indicate below	the file number assigned	to the registrant in connec	tion with Rule 12g3-2(b): 82-

PreMD Inc. Form 6-K

On July 12, 2006, the Corporation issued a news release announcing interim results from the PREPARE (<u>PREVU*</u> <u>Predicts Atherosclerosis Risk and Events</u>) study, which is being conducted in the life insurance industry with selected U.S. life insurers using PREVU* LT Skin Sterol Test. The information contained in the news release is incorporated herein by reference and filed as Exhibit 99.1.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

PreMD Inc.

By: /s/ Ronald G. Hosking

Ronald G. Hosking

Vice President and Chief Financial Officer

Date: July 12, 2006

EXHIBIT INDEX

Exhibit

Number Description

The Registrant's News Release Dated July 12, 2006 99.1